| 000 | 01730 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515055718.0 | ||
| 264 | 0 | _c20070425 | |
| 008 | 200704s 0 0 eng d | ||
| 022 | _a0009-9236 | ||
| 024 | 7 |
_a10.1038/sj.clpt.6100084 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHamberg, A-K | |
| 245 | 0 | 0 |
_aA PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cApr 2007 |
||
| 300 |
_a529-38 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAging _xmetabolism |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 |
_aDNA _xgenetics |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xgenetics |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aPharmacokinetics |
| 650 | 0 | 4 | _aPopulation |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aVitamin K Epoxide Reductases |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aDahl, M-L | |
| 700 | 1 | _aBarban, M | |
| 700 | 1 | _aScordo, M G | |
| 700 | 1 | _aWadelius, M | |
| 700 | 1 | _aPengo, V | |
| 700 | 1 | _aPadrini, R | |
| 700 | 1 | _aJonsson, E N | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 81 _gno. 4 _gp. 529-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.clpt.6100084 _zAvailable from publisher's website |
| 999 |
_c16861094 _d16861094 |
||